Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (51-60 of 868) with videos related to

Pageof 87
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Gauging progress in a decades-old fightJesse Potash, Kenneth C Anderson
Nature Reviews. Clinical Oncology|May 12, 2023
Determinants of response and resistance to T cell-engaging therapies in multiple myelomaShonali Midha, Kenneth C Anderson
Current Opinion in Oncology|November 1, 2002
Thalidomide and immunomodulatory drugs as cancer therapyNoopur Raje, Kenneth C Anderson
Cell Cycle (Georgetown, Tex.)|April 21, 2010
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathwaysKlaus Podar, Kenneth C Anderson
Seminars in Hematology|June 26, 2012
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studiesTeru Hideshima, Kenneth C Anderson
Cancer Letters|February 14, 2006
Caveolin-1 as a potential new therapeutic target in multiple myelomaKlaus Podar, Kenneth C Anderson
Nature Clinical Practice. Oncology|November 3, 2005
Drug insight: thalidomide as a treatment for multiple myelomaShaji Kumar, Kenneth C Anderson
Cancers|January 13, 2021
Signaling Pathway Mediating Myeloma Cell Growth and SurvivalTeru Hideshima, Kenneth C Anderson
Expert Opinion on Drug Metabolism & Toxicology|July 16, 2008
Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicityIris Breitkreutz, Kenneth C Anderson
Hematology/Oncology Clinics of North America|November 13, 2007
Preclinical studies of novel targeted therapiesTeru Hideshima, Kenneth C Anderson
Pageof 87

Showing results (51-60 of 868) with videos related to

Sort By:
Pageof 87
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Gauging progress in a decades-old fightJesse Potash, Kenneth C Anderson
Nature Reviews. Clinical Oncology|May 12, 2023
Determinants of response and resistance to T cell-engaging therapies in multiple myelomaShonali Midha, Kenneth C Anderson
Current Opinion in Oncology|November 1, 2002
Thalidomide and immunomodulatory drugs as cancer therapyNoopur Raje, Kenneth C Anderson
Cell Cycle (Georgetown, Tex.)|April 21, 2010
A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathwaysKlaus Podar, Kenneth C Anderson
Seminars in Hematology|June 26, 2012
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studiesTeru Hideshima, Kenneth C Anderson
Cancer Letters|February 14, 2006
Caveolin-1 as a potential new therapeutic target in multiple myelomaKlaus Podar, Kenneth C Anderson
Nature Clinical Practice. Oncology|November 3, 2005
Drug insight: thalidomide as a treatment for multiple myelomaShaji Kumar, Kenneth C Anderson
Cancers|January 13, 2021
Signaling Pathway Mediating Myeloma Cell Growth and SurvivalTeru Hideshima, Kenneth C Anderson
Expert Opinion on Drug Metabolism & Toxicology|July 16, 2008
Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicityIris Breitkreutz, Kenneth C Anderson
Hematology/Oncology Clinics of North America|November 13, 2007
Preclinical studies of novel targeted therapiesTeru Hideshima, Kenneth C Anderson
Pageof 87